Standout Papers

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer 2010 2026 2015 2020 5.4k
  1. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer (2011)
    Thierry Conroy, Françoise Desseigne et al. New England Journal of Medicine
  2. Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2 (2010)
    Jean‐Pierre Gérard, D. Azria et al. Journal of Clinical Oncology

Citation Impact

3 by Nobel laureates 20 from Science/Nature 84 standout
Sub-graph 1 of 20

Citing Papers

Colorectal cancer
2024 Standout
Pancreatic cancer: Advances and challenges
2023 Standout
33 intermediate papers

Works of Y. Bécouarn being referenced

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial
2007
and 7 more

Author Peers

Author Oncology PRM Surgery Last Decade Papers Cites
Y. Bécouarn 6868 2169 2261 84 7.9k
Erica S. Savig 86 10 12 5 533
Akira Shiraki 49 299 42 30 504
Mikhaila Burgess 1 6 273
Bradley M. Ratliff 34 644
Patricia P. Mahlstedt 1 3 1 7 496

All Works

Loading papers...

Rankless by CCL
2026